

Figure 1E. HCV29R^{wt}mTOR Diff concentrations




Figure 2A MRD525 Diff Concentrations




Figure 2B MRD639 Diff cons.




Figure 1F. HCV29RP mTOR IP





Figure 2D. 105KRP mTOR IP





Figure 2C. MRD mTOR IP





Figure S1E. TSC1 MEFs RP^{wt} mTOR Diff concentrations




Figure S1F TSC2 MEFs RP Diff Concentrations




Figure S1G. 705RP Diff concentrations




Figure S1H. RT4 RP Diff Concentrations




Figure S1I. 97-1RP Diff concentrations




Figure S1J. SNU886 RP Diff concentrations




Figure S1K. H101RP Diff Concentrations




Figure S2E. 105KRP Diff concentrations




Figure S2A. TSC1 MEFs RP mTOR IP





Figure S2B. TSC2 MEFs RP mTOR IP





Figure S2C. 705KRP mTOR IP





Figure S2D. 97-1RP mTOR IP




Figure 9A. RP vs Parental cell lines




Figure 9B. m705RP with siRNA or inhibitors




Figure 9D. PDX tumors




Figure 9C. RP treated by inhibitors




Figure S7A. MYC OE

